- Home
- DAVI vs ARCT Comparison
DAVI vs ARCT Comparison
Compare DAVI & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$0.91
N/A
Current Price
$8.37
Company Overview
Basic Information| Metric | DAVI | ARCT |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.3M | 293.9M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DAVI | ARCT |
|---|---|---|
| Price | $0.91 | $8.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | 435.8K | ★ 653.3K |
| Earning Date | 04-06-2027 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.20 | $5.50 |
| 52 Week High | $6.05 | $17.96 |
Technical Indicators
Market Signals| Indicator | DAVI | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 12.25 | 36.93 |
| Support Level | N/A | $6.45 |
| Resistance Level | $1.80 | $8.69 |
| Average True Range (ATR) | 0.41 | 1.06 |
| MACD | -0.09 | -0.12 |
| Stochastic Oscillator | 0.03 | 5.32 |
Price Performance
Historical Comparison DAVI
ARCT
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.